TOX2 regulates human natural killer cell development by controlling T-BET expression

Blood

Volumn 124, Issue 26, 2014, Pages 3905-3913

  Vong, Queenie P ^a   Leung, Wai Hang ^a   Houston, Jim ^a   Li, Ying ^a   Rooney, Barbara ^a   Holladay, Martha ^a   Oostendorp, Robert A J ^b   Leung, Wing ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B PROTEIN; THYMOCYTE SELECTION ASSOCIATED HIGH MOBILITY GROUP BOX PROTEIN FAMILY MEMBER 2; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; CD34 ANTIGEN; PROTEIN BINDING; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21; TOX2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; UMBILICAL CORD BLOOD; UPREGULATION; ANIMAL; CYTOLOGY; DNA MICROARRAY; EMBRYOLOGY; FETUS BLOOD; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEK293 CELL LINE; LENTIVIRINAE; LIVER; LYMPHOCYTE; METABOLISM; NONOBESE DIABETIC MOUSE; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIGENS, CD34; CELL DIFFERENTIATION; FETAL BLOOD; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE SILENCING; HEK293 CELLS; HMGB PROTEINS; HUMANS; KILLER CELLS, NATURAL; LENTIVIRUS; LIVER; LYMPHOCYTES; MICE; MICE, INBRED NOD; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; T-BOX DOMAIN PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84919493623     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-582965     Document Type: Article

References (32)

1. Freud AG, Yu J, Caligiuri MA. Human natural killer cell development in secondary lymphoid tissues. Semin Immunol. 2014;26(2):132-137.
2. Cichocki F, Sitnicka E, Bryceson YT. NK cell development and function - plasticity and redundancy unleashed. Semin Immunol. 2014;26(2):114-126.
3. Marc¸ais A, Viel S, Grau M, Henry T, Marvel J, Walzer T. Regulation of mouse NK cell development and function by cytokines. Front Immunol. 2013;4:450.
4. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7(9):703-714.
5. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98-109.
6. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14-32.
7. Hesslein DG, Lanier LL. Transcriptional control of natural killer cell development and function. Adv Immunol. 2011;109:45-85.
8. Luevano M, Madrigal A, Saudemont A. Transcription factors involved in the regulation of natural killer cell development and function: an update. Front Immunol. 2012;3:319.
9. Gascoyne DM, Long E, Veiga-Fernandes H, et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol. 2009;10(10):1118-1124.
10. Male V, Nisoli I, Kostrzewski T, et al. The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J Exp Med. 2014;211(4):635-642.
11. Ramirez K, Chandler KJ, Spaulding C, et al. Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1. Immunity. 2012;36(6):921-932.
12. Boos MD, Yokota Y, Eberl G, Kee BL. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med. 2007;204(5):1119-1130.
13. Townsend MJ, Weinmann AS, Matsuda JL, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity. 2004;20(4):477-494.
14. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol. 2007;8(12):1337-1344.
15. Gordon SM, Chaix J, Rupp LJ, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 2012;36(1):55-67.
16. Daussy C, Faure F, Mayol K, et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med. 2014;211(3):563-577.
17. Aliahmad P, de la Torre B, Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol. 2010;11(10):945-952.
18. Tessema M, Yingling CM, Grimes MJ, et al. Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS ONE. 2012;7(4):e34850.
19. Kajitani T, Mizutani T, Yamada K, et al. Cloning and characterization of granulosa cell high-mobility group (HMG)-box protein-1, a novel HMG-box transcriptional regulator strongly expressed in rat ovarian granulosa cells. Endocrinology. 2004;145(5):2307-2318.
20. Aliahmad P, Kaye J. Development of all CD4 T lineages requires nuclear factor TOX. J Exp Med. 2008;205(1):245-256.
21. Aliahmad P, Kadavallore A, de la Torre B, Kappes D, Kaye J. TOX is required for development of the CD4 T cell lineage gene program. J Immunol. 2011;187(11):5931-5940.
22. Grzywacz B, Kataria N, Sikora M, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006;108(12):3824-3833.
23. McCullar V, Oostendorp R, Panoskaltsis-Mortari A, et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol. 2008;36(5):598-608.
24. Freud AG, Yokohama A, Becknell B, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med. 2006;203(4):1033-1043.
25. Montaldo E, Del Zotto G, Della Chiesa M, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A. 2013;83(8):702-713.
26. Strowig T, Chijioke O, Carrega P, et al. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood. 2010;116(20):4158-4167.
27. Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009;206(1):25-34.
28. Leung WH, Vong QP, Lin W, Janke L, Chen T, Leung W. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRg activation. J Exp Med. 2013;210(12):2675-2692.
29. Smith C, Elhassen D, Gras S, et al. Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. Blood. 2012;120(16):3237-3245.
30. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013;15(4):216.
31. Liang X, Graham DK. Natural killer cell neoplasms. Cancer. 2008;112(7):1425-1436.
32. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. 2011;155(1):14-29.